Anything is possible. Of course it would depend on things like what they acquired, how they paid for it, potential value, little things like that and probably a few dozen others. The real question is why does this company continue to miss its own self-defined milestones (licensing, publishing of ovarian cancer article, additional metals contracts, break-out year, delivery to MDA, etc.). That "lofty pps" of .195, as you referred to it, would only be seen in the rearview mirror if/when the Flynn technology can actually be proven to work imo. The continued delays and missed milestones are worrisome.
News 
Market Data 
Discover 
